Emtricitabine/Tenofovir disoproxil Krka
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Emtricitabine;tenofovir disoproxil
- Made by
- KRKA, d.d., Novo mesto
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of HIV-1 infection Emtricitabine/tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1 Pre-exposure prophylaxis (PrEP) Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | KRKA, d.d., Novo mesto |
|---|---|
| Active substance | Emtricitabine;tenofovir disoproxil |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR03 · Antibiotics, antivirals and antifungals taken into the body |
| Generic | Yes — a generic medicine, according to the register |
| Authorised on | 2016-12-09 |
| Last updated by the regulator | 2025-01-31 |
| EMA product number | EMEA/H/C/004215 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.